Multiple Sclerosis Market Scope And Analysis

  • Report Code : TIPRE00004597
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Multiple Sclerosis Therapeutics Market Size and Scope - 2031

Buy Now

Multiple Sclerosis Therapeutics Market Report Multiple Sclerosis Therapeutics Market Size and Share Multiple Sclerosis Therapeutics Market Scope and Analysis

Multiple Sclerosis Therapeutics Market Report Scope

Report Attribute Details
Market size in 2024 US$ 31.87 Billion
Market Size by 2031 US$ 53.77 Billion
Global CAGR (2025 - 2031) 6.8%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable and Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Merck and CO Inc
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristoll Myers Squibb
  • Horizon Therapeutics
  • Teva Pharmaceuticals
  • Takeda Pharmaceuticals
  • F Hoffmann La Roche
  • Biogen

    • Multiple Sclerosis Therapeutics Market News and Recent Developments

    The Multiple Sclerosis Therapeutics Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for multiple sclerosis therapeutics and strategies:

    • The US Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). (Source: Food and Drug Administration, Press Release, 2023)
    • Neuraxpharm Group launched BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease. Germany is the first country in Europe to see the launch of ublituximab. This follows Neuraxpharm’s agreement with TG Therapeutics, announced in August 2023, to commercialise ublituximab outside the United States (US), Canada, Mexico and excluding certain Asian countries that have been previously partnered. (Source: William Reed, Company Website, 2024)

    Multiple Sclerosis Therapeutics Market Report Coverage and Deliverables

    The “Multiple Sclerosis Therapeutics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles